Description

Moderna Just Put mRNA Back In The Flu Shot Debate!

Moderna has a fresh regulatory win in the flu vaccine race. An FDA advisory committee voted that the benefits of its seasonal flu vaccine, mRNA-1010, exceed the risks for adults aged 50 to 64 and adults 65 and older. That is a meaningful step because flu shots are familiar to most Americans, but mRNA flu vaccines still feel new to many of them. The bigger story is not just whether the FDA approves the vaccine. The real test is whether Moderna can turn scientific and regulatory progress into public acceptance, payer support, and repeat seasonal demand. The company is trying to prove that mRNA was not only a COVID-era technology, but a broader platform for respiratory disease, cancer, rare disease, and other large markets. The timing matters. Moderna’s earnings call showed that the U.S.